Neovascular age-related macular degeneration is a major cause of retinal blindness in the aging population and age related macular degeneration (AMD). Current treatment approaches are focused on antagonizing a single factor that controls growth of new blood vessels, vascular endothelial growth factor (VEGF). In collabotration with Dr. Kume in cardiology, we would like to explore a newly described transcription factor that may have a role controlling several pathways in angiogenesis. Our hope is to identify potential new targets for therapy of retinal neovascularization in the setting of AMD. We would like to start a collaboration between our lab and Dr. Kume’s group to explore the role of foxc2 in retinal angiogenesis.
|Effective start/end date||7/1/12 → 6/30/13|
- Illinois Society for the Prevention of Blindness (Award Letter 1/30/2013)